Clinical and therapeutic developmentPhase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease
References (13)
- et al.
Life Sci.
(1993) Brain Res.
(1979)- et al.
Prog. Neuropharmacol.-Biol.-Psychiatry
(1986) - et al.
Neurosci. Lett.
(1991) - et al.
Science
(1982) - et al.
Science
(1982)
There are more references available in the full text version of this article.
Cited by (25)
pH-dependent solubility and permeability profiles: A useful tool for prediction of oral bioavailability
2017, European Journal of Pharmaceutical SciencesStructural basis for high substrate-binding affinity and enantioselectivity of 3-quinuclidinone reductase AtQR
2014, Biochemical and Biophysical Research CommunicationsCitation Excerpt :The compound is intended for muscarinic substitution therapy in patients with Alzheimer’s disease. Talsaclidine appears to be a promising new candidate because even high doses cause only salivation as a side effect in healthy volunteers [4]. (R)-3-quinuclidinol is used as a chiral building block applicable to the synthesis of various pharmaceuticals including talsaclidine [5–9].
Copyright © 1995 Published by Elsevier Inc.